Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition Test Bank (Arcangelo) - 2025 APRN & PharmD Guide

TEST BANK g


PharmacotherapeuticsgforgAdvancedgPractice:gAgPracticalgApproach

bygVirginiagPoolegArcangelo,gAndrewgM.gPeterson
FifthgEdition




FULL TEST BANK!!!
g g

,Chapterg1gIssuesgforgthegPractitionergingDruggTherapy

MULTIPLEgCHOICE

1. Nursegpractitionergprescriptivegauthoritygisgregulatedgby:
A. ThegNationalgCouncilgofgStategBoardsgofgNursing
B. ThegU.S.gDruggEnforcementgAdministration
C. ThegStategBoardgofgNursinggforgeachgstate
D. ThegStategBoardgofgPharmacy

ANS:g C PTS:g 1

2. PhysiciangAssistantg(PA)gprescriptivegauthoritygisgregulatedgby:
A. ThegNationalgCouncilgofgStategBoardsgofgNursing
B. ThegU.S.gDruggEnforcementgAdministration
C. ThegStategBoardgofgNursing
D. ThegStategBoardgofgMedicalgExaminers

ANS:g D PTS:g 1

3. Clinicalgjudgmentgingprescribinggincludes:
A. Factoringgingthegcostgtogthegpatientgofgthegmedicationgprescribed
B. Alwaysgprescribinggthegnewestgmedicationgavailablegforgthegdiseasegprocess
C. Handinggoutgdruggsamplesgtogpoorgpatients
D. Prescribinggallggenericgmedicationsgtogcutgcosts

ANS:g A PTS:g 1

4. Criteriagforgchoosinggangeffectivegdruggforgagdisorderginclude:
A. Askinggthegpatientgwhatgdruggtheygthinkgwouldgworkgbestgforgthem
B. Consultinggnationallygrecognizedgguidelinesgforgdiseasegmanagement
C. Prescribinggmedicationsgthatgaregavailablegasgsamplesgbeforegwritinggagprescription
D. FollowinggU.S.gDruggEnforcementgAdministrationg(DEA)gguidelinesgfo
rgprescribing
ANS:g B PTS:g 1

5. Nursegpractitionergpracticegmaygthrivegunderghealth-caregreformgduegto:
A. Thegdemonstratedgabilitygofgnursegpractitionersgtogcontrolgcostsgandgimprovegpatie
ntgoutcomes
B. Thegfactgthatgnursegpractitionersgwillgbegablegtogpracticegindependently
C. Thegfactgthatgnursegpractitionersgwillghavegfullgreimbursementgunderghealth-
caregreform
D. ThegabilitygtogshiftgaccountabilitygforgMedicaidgtogthegstateglevel
ANS:g A PTS:g 1

, g
lOMoAR cPSD|




g 21007614




Chapterg2.PharmacokineticgBasisgofgTherapeuticsgandgPharmacodynamic

MULTIPLEgCHOICE

1. Agpatient'sgnutritionalgintakegandglabgworkgreflectsghypoalbuminemia.gThisgisgcriticalgt
ogprescribinggbecause:
A. Distributiongofgdrugsgtogtargetgtissuegmaygbegaffected
B. Thegsolubilitygofgthegdruggwillgnotgmatchgthegsitegofgabsorption
C. Theregwillgbeglessgfreegdruggavailablegtoggenerategangeffect
D. Drugsgboundgtogalbumingaregreadilygexcretedgbygthegkidney

ANS:g A PTS:g 1

2. Drugsgthatghavegagsignificantgfirst-passgeffect:
A. Mustgbeggivengbygthegenteralg(oral)groutegonly
B. Bypassgtheghepaticgcirculation
C. Aregrapidlygmetabolizedgbygtheglivergandgmayghaveglittlegifganygdesiredgaction
D. Aregconvertedgbygtheglivergtogmoregactivegandgfat-solublegforms

ANS:g C PTS:g 1

3. Thegroutegofgexcretiongofgagvolatilegdruggwillglikelygbe:
A. Thegkidneys
B. Theglungs
C. Thegbilegandgfeces
D. Thegskin

ANS:g B PTS:g 1

4. Medroxyprogesteroneg(DepogProvera)gisgprescribedgIMgtogcreategagstoragegreservoirgofgth
egdrug.gStoragegreservoirs:
A. Assuregthatgthegdruggwillgreachgitsgintendedgtargetgtissue
B. Aregthegreasongforggivinggloadinggdoses
C. Increasegtheglengthgofgtimegagdruggisgavailablegandgactive
D. Aregmostgcommongingcollagengtissues

ANS:g C PTS:g 1

5. ThegNPgchoosesgtoggivegcephalexingeveryg8ghoursgbasedgongknowledgegofgthegdrug's:
A. Propensitygtoggogtogthegtargetgreceptor
B. Biologicalghalf-life
C. Pharmacodynamics
D. Safetygandgsidegeffects

ANS:g B PTS:g 1

6. Azithromycingdosinggrequiresgthegfirstgday'sgdosegbegtwicegthosegofgthegotherg4gdaysgofgt
hegprescription.gThisgisgconsideredgagloadinggdose.gAgloadinggdose:
A. Rapidlygachievesgdrugglevelsgingthegtherapeuticgrange
B. Requiresgfourgtogfiveghalf-livesgtogattain
C. Isginfluencedgbygrenalgfunction

, g
lOMoAR cPSD|




g 21007614




D. Isgdirectlygrelatedgtogthegdruggcirculatinggtogthegtargetgtissues
ANS:g A PTS:g g 1

7. Thegpointgingtimegongthegdruggconcentrationgcurvegthatgindicatesgthegfirstgsigngofgagtherapeut
icgeffectgisgthe:
A. Minimumgadversegeffectglevel
B. Peakgofgaction
C. Onsetgofgaction
D. Therapeuticgrange

ANS:g C PTS:g 1

8. Phenytoingrequiresgagtroughglevelgbegdrawn.gPeakgandgtroughglevelsgaregdone:
A. Whengthegdrugghasgagwidegtherapeuticgrange
B. Whengthegdruggwillgbegadministeredgforgagshortgtimegonly
C. Whengtheregisgaghighgcorrelationgbetweengthegdosegandgsaturationgofgreceptorgsites
D. Togdeterminegifgagdruggisgingthegtherapeuticgrange

ANS:g D PTS:g 1

9. Aglaboratorygresultgindicatesgthegpeakglevelgforgagdruggisgabovegthegminimumgtoxi
cgconcentration.gThisgmeansgthatgthe:
A. Concentrationgwillgproducegtherapeuticgeffects
B. Concentrationgwillgproducegangadversegresponse
C. Timegbetweengdosesgmustgbegshortened
D. Durationgofgactiongofgthegdruggisgtooglong

ANS:g B PTS:g 1

10. Drugsgthatgaregreceptorgagonistsgmaygdemonstrategwhatgproperty?
A. Irreversiblegbindinggtogthegdruggreceptorgsite
B. Up-regulationgwithgchronicguse
C. Desensitizationgorgdown-regulationgwithgcontinuousguse
D. Inversegrelationshipgbetweengdruggconcentrationgandgdruggaction

ANS:g C PTS:g 1

11. Drugsgthatgaregreceptorgantagonists,gsuchgasgbetagblockers,gmaygcause:
A. Down-regulationgofgthegdruggreceptor
B. Angexaggeratedgresponsegifgabruptlygdiscontinued
C. Partialgblockadegofgthegeffectsgofgagonistgdrugs
D. Angexaggeratedgresponsegtogcompetitivegdruggagonists

ANS:g B PTS:g 1

12. Factorsgthatgaffectggastricgdruggabsorptionginclude:
A. Livergenzymegactivity
B. Protein-bindinggpropertiesgofgthegdruggmolecule
C. Lipidgsolubilitygofgthegdrug
D. Abilitygtogchewgandgswallow

ANS:g C PTS:g 1




WWW.TEGTBANKTANK.COM